Angiotensin II receptor antagonists role in arterial hypertension
- 1 March 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Human Hypertension
- Vol. 16 (S1), S93-S99
- https://doi.org/10.1038/sj.jhh.1001352
Abstract
Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT(1) receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT(1) receptor blockers antagonise all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the AT(1) receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT(1) receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being with low incidence of side effects even at long term use. Monotherapy in mild-to-moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of thiazide diuretic is added, 60-70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium antagonists and beta-blocking agents. AT(1) receptor blockers are specially indicated in patients with hypertension who are being treated with ACE inhibitors and developed side effects such as, cough or angioedema. The final position in the antihypertensive therapy in this special population and other clinical situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clinical trials, some of which are now being conducted and seem promising.This publication has 41 references indexed in Scilit:
- Mechanistic Differences of Various AT 1 -Receptor Blockers in Isolated Vessels of Different OriginHypertension, 1999
- ValsartanDrugs, 1997
- Double‐Blind Comparison of Losartan, Lisinopril, and Metolazone in Elderly Hypertensive Patients with Previous Angiotensin‐Converting Enzyme Inhibitor‐Induced CoughThe Journal of Clinical Pharmacology, 1997
- Role of Type 1 and Type 2 Angiotensin Receptors in Angiotensin II–Induced Cardiomyocyte HypertrophyHypertension, 1996
- Effects of Losartan on a Background of Hydrochlorothiazide in Patients With HypertensionHypertension, 1995
- Proposed Update of Angiotensin Receptor NomenclatureHypertension, 1995
- Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive ratsLife Sciences, 1992
- Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats.Hypertension, 1992
- Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.Hypertension, 1990
- Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulationProgress in Cardiovascular Diseases, 1974